Equities analysts predict that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings per share (EPS) of ($1.23) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($1.41). Ascendis Pharma A/S posted earnings of ($1.22) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 0.8%. The company is expected to report its next earnings report on Thursday, November 15th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($4.22) per share for the current financial year, with EPS estimates ranging from ($4.83) to ($3.18). For the next fiscal year, analysts forecast that the firm will report earnings of ($3.50) per share, with EPS estimates ranging from ($5.79) to ($0.28). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, August 29th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.03) by $0.37. Ascendis Pharma A/S had a negative net margin of 17,641.85% and a negative return on equity of 49.69%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.16 million.
A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, August 7th. They set a “buy” rating and a $81.00 price target for the company. BidaskClub upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Friday, October 19th. ValuEngine upgraded shares of Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “strong-buy” rating and set a $72.00 price target for the company in a research report on Tuesday. Finally, Stifel Nicolaus reduced their price target on shares of Ascendis Pharma A/S from $85.00 to $81.00 and set a “buy” rating for the company in a research report on Thursday, August 30th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $76.67.
Shares of ASND stock traded down $0.42 during midday trading on Friday, reaching $64.50. 107,050 shares of the company traded hands, compared to its average volume of 118,748. Ascendis Pharma A/S has a 1-year low of $33.50 and a 1-year high of $76.99. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -14.90 and a beta of 0.82.
Several institutional investors and hedge funds have recently modified their holdings of ASND. Orbimed Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 31.1% during the 2nd quarter. Orbimed Advisors LLC now owns 4,413,291 shares of the biotechnology company’s stock worth $293,572,000 after purchasing an additional 1,045,976 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in Ascendis Pharma A/S in the 2nd quarter worth approximately $5,795,000. Renaissance Technologies LLC grew its stake in Ascendis Pharma A/S by 750.9% in the 2nd quarter. Renaissance Technologies LLC now owns 56,500 shares of the biotechnology company’s stock worth $3,758,000 after acquiring an additional 49,860 shares during the period. BlackRock Inc. grew its stake in Ascendis Pharma A/S by 8.1% in the 2nd quarter. BlackRock Inc. now owns 438,789 shares of the biotechnology company’s stock worth $29,188,000 after acquiring an additional 32,980 shares during the period. Finally, Bank of America Corp DE grew its stake in Ascendis Pharma A/S by 605.4% in the 2nd quarter. Bank of America Corp DE now owns 31,813 shares of the biotechnology company’s stock worth $2,116,000 after acquiring an additional 27,303 shares during the period. 93.93% of the stock is owned by institutional investors and hedge funds.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
See Also: How Short Selling Works
Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.